Cheap, 'generic' drug reduces COVID-19 death risk by 75 percent, trials suggest
Ivermectin, a cheap and "generic" antiparasitic drug "used all over the world," may significantly reduce the risk of death in patients suffering from moderate to severe cases of COVID-19, researchers have found.
The University of Liverpool's Andrew Hill and others carried out a meta-analytical breakdown of 18 studies that showed the drug — which is off-patent and commonly used to treat lice and scabies, as well as some more serious parasites — appears to reduce inflammation and eliminate the coronavirus swiftly, the Financial Times reports. In six of those trials, the mortality risk was cut by 75 percent in patients with more serious COVID-19 infections. The research team has also theorized the drug could also make it harder for infected people to transmit the virus.
Hill said he's encouraged by the findings, but further studies are needed, especially since several of those in the analysis were not peer-reviewed. FT also notes that meta-analyses, which look at many studies at once, can be prone to errors. Read more at the Financial Times.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Why are people microdosing Ozempic?
In The Spotlight Tiny doses of the weight-loss drug can sidestep its unpleasant side effects, say influencers. But is customising the dose a good idea?
By Chas Newkey-Burden, The Week UK Published
-
Five festive cocktails for Christmas 2024
The Week Recommends Serve seasonal libations for an extra special gathering
By Adrienne Wyper, The Week UK Published
-
Octopuses could be the next big species after humans
UNDER THE RADAR What has eight arms, a beaked mouth, and is poised to take over the planet when we're all gone?
By Rafi Schwartz, The Week US Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published
-
Bird flu one mutuation from human threat, study finds
Speed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
By Peter Weber, The Week US Published
-
Dark chocolate tied to lower diabetes risk
Speed Read The findings were based on the diets of about 192,000 US adults over 34 years
By Peter Weber, The Week US Published
-
ACA opens 2025 enrollment, enters 2024 race
Speed Read Mike Johnson promises big changes to the Affordable Care Act if Trump wins the election
By Peter Weber, The Week US Published
-
McDonald's sued over E. coli linked to burger
Speed Read The outbreak has sickened at least 49 people in 10 states and left one dead
By Rafi Schwartz, The Week US Published
-
Texas dairy worker gets bird flu from infected cow
Speed Read The virus has been spreading among cattle in Texas, Kansas, Michigan and New Mexico
By Peter Weber, The Week US Published
-
Dengue hits the Americas hard and early
Speed Read Puerto Rico has declared an epidemic as dengue cases surge
By Peter Weber, The Week US Published
-
US bans final type of asbestos
Speed Read Exposure to asbestos causes about 40,000 deaths in the U.S. each year
By Peter Weber, The Week US Published